Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

Targeted therapies including the engineered afucosylated anti-CD20 monoclonal antibody obinutuzumab, Bruton’s tyrosine kinase inhibitor ibrutinib, and B-cell lymphoma protein 2 inhibitor venetoclax have demonstrated significant clinical activity in chronic lymphocytic leukemia (CLL) and, based on th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Rogers, Kerry A., Huang, Ying, Ruppert, Amy S., Awan, Farrukh T., Heerema, Nyla A., Hoffman, Corinne, Lozanski, Gerard, Maddocks, Kami J., Moran, Mollie E., Reid, Mark A., Lucas, Margaret, Woyach, Jennifer A., Whitlow, W. Thomas, Jones, Jeffrey A., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6182267/
https://ncbi.nlm.nih.gov/pubmed/30111609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-05-853564
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados